Bausch Health Companies Inc. Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed
Bausch Health Companies Inc. (BHC) reported Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed of $43.00 million for the 12-month period ending 2015-12-31, per its 10-K filed 2016-04-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed · last filed 2016-04-29
- Bausch Health Companies Inc. business combination, separately recognized transactions, additional disclosures, acquisition cost expensed for fiscal 2015 was $43.00M, a 64.75% decline from fiscal 2014.
- Bausch Health Companies Inc. business combination, separately recognized transactions, additional disclosures, acquisition cost expensed for fiscal 2014 was $122.00M.
| Period end | Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed 12 month |
|---|---|
| 2015-12-31 | $43.00M 10-K · filed 2016-04-29 |
| 2014-12-31 | $122.00M 10-K · filed 2015-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |